Epo/GCSF Response in MDS

By clicking on the “Submit” button below, you acknowledge that you have read, understand, and agree to be bound by the terms of the QxMD Online Calculator End User Agreement.

Use this calculator to predict reponse to Epo and GCSF in Myelodysplastic Syndrome.

Serum erythropoeitin
Transfusion needs

About this calculator

In general, treatment with erythropoietin (EPO) may improve anemia in about 15-20% of patients with myelodysplastic syndromes (MDS). The combination of EPO and granulocyte colony-stimulating factor (GCSF) may improve response rates to around 40%. This predictive model uses two variables (serum EPO and transfusion need) to identify those who are most likely to respond to these stem-cell factors. The model was developed and validated predominantly in patients with low-risk MDS. Response is defined as a 100% reduction in RBC transfusion need or an increase in hemoglobin level by at least 1.5 g/L.

Citation

Hellstrom-Lindberg et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haem 99:344-351. (1997)

Contributor

QxMD Hematology contributing author: Dr. Matthew Cheung, MD, SM, FRCP(C)